Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial
Dean Follmann, Holly E. Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks, Karen Kotloff, Michaël Desjardins, Lawrence Corey, Kathleen M. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, Lindsey R. Baden
doi: https://doi.org/10.1101/2022.04.18.22271936
